达雷妥尤单抗、卡非佐米、来那度胺和地塞米松联合方案用于新诊断多发性骨髓瘤的微小残留病应答适应性治疗
MASTER试验是一项多中心、单臂、II期研究,纳入123例新诊断多发性骨髓瘤(NDMM)患者,采用达雷妥尤单抗、卡非佐米、来那度胺和地塞米松(Dara-KRd)方案,根据二代测序(NGS)检测的微小残留病(MRD)状态指导自体造血干细胞移植(AHCT)后Dara-KRd的使用和持续时间,以及连续两次MRD阴性患者的治疗终止。主要终点为MRD阴性(<10^-5)达成率。
要点
- 80%患者达到MRD阴性(<10^-5),66%达到MRD<10^-6,71%达到连续两次MRD阴性并进入无治疗监测。
- 2年无进展生存率为87%;0、1和2+个高危细胞遗传学异常(HRCA)患者分别为91%、97%和58%。
- 停止治疗后12个月MRD复燃或进展的累积发生率在0、1和2+个HRCA患者中分别为4%、0%和27%。
核心结论
- Dara-KRd、AHCT和MRD应答适应性巩固治疗在新诊断多发性骨髓瘤中实现高MRD阴性率;对于0或1个HRCA患者,该策略创造了以MRD监测替代无限期维持治疗的机会。
研究设计与样本
- 多中心、单臂、II期试验(MASTER),纳入123例新诊断多发性骨髓瘤患者,计划富集高危细胞遗传学异常(HRCA);患者接受Dara-KRd诱导、AHCT和根据MRD状态进行的Dara-KRd巩固治疗;MRD通过NGS在诱导结束时、AHCT后和每4个巩固周期(最多8周期)评估;主要终点为MRD阴性(<10^-5)达成率;连续两次MRD阴性患者进入无治疗MRD监测。
主要发现
- 在123例参与者中,43%无HRCA,37%有1个HRCA,20%有2+个HRCA;中位年龄60岁(范围36-79岁),96%患者MRD可通过NGS追踪;中位随访25.1个月。
- 总体80%患者达到MRD阴性(0、1和2+个HRCA患者分别为78%、82%和79%),66%达到MRD<10^-6,71%在治疗期间达到连续两次MRD阴性评估并进入无治疗监测。
- 2年无进展生存率为87%(0、1和2+个HRCA患者分别为91%、97%和58%)。
- 停止治疗后12个月MRD复燃或进展的累积发生率在0、1和2+个HRCA患者中分别为4%、0%和27%。
- 最常见的严重不良事件为肺炎(6%)和静脉血栓栓塞(3%)。
临床怎么用
- 对于0或1个HRCA的新诊断多发性骨髓瘤患者,Dara-KRd、AHCT和MRD应答适应性巩固治疗策略创造了以MRD监测替代无限期维持治疗的机会;作者认为该策略在0或1个HRCA患者中可实现此机会。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The MASTER trial combined daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in newly diagnosed multiple myeloma (NDMM), using minimal residual disease (MRD) by next-generation sequencing (NGS) to inform the use and duration of Dara-KRd post-autologous hematopoietic cell transplantation (AHCT) and treatment cessation in patients with two consecutive MRD-negative assessments. METHODS: This multicenter, single-arm, phase II trial enrolled patients with NDMM with planed enrichment for high-risk cytogenetic abnormalities (HRCAs). Patients received Dara-KRd induction, AHCT, and Dara-KRd consolidation, according to MRD status. MRD was evaluated by NGS at the end of induction, post-AHCT, and every four cycles (maximum of eight cycles) of consolidation. Primary end point was achievement of MRD negativity (< 10-5). Patients with two consecutive MRD-negative assessments entered treatment-free MRD surveillance. RESULTS: Among 123 participants, 43% had none, 37% had 1, and 20% had 2+ HRCA. Median age was 60 years (range, 36-79 years), and 96% had MRD trackable by NGS. Median follow-up was 25.1 months. Overall, 80% of patients reached MRD negativity (78%, 82%, and 79% for patients with 0, 1, and 2+ HRCA, respectively), 66% reached MRD < 10-6, and 71% reached two consecutive MRD-negative assessments during therapy, entering treatment-free surveillance. Two-year progression-free survival was 87% (91%, 97%, and 58% for patients with 0, 1, and 2+ HRCA, respectively). Cumulative incidence of MRD resurgence or progression 12 months after cessation of therapy was 4%, 0%, and 27% for patients with 0, 1, or 2+ HRCA, respectively. Most common serious adverse events were pneumonia (6%) and venous thromboembolism (3%). CONCLUSION: Dara-KRd, AHCT, and MRD response-adapted consolidation leads to high rate of MRD negativity in NDMM. For patients with 0 or 1 HRCA, this strategy creates the opportunity of MRD surveillance as an alternative to indefinite maintenance.
引用
- Costa LJ, Chhabra S, Medvedova E, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2021. PMID: 34898239. doi:10.1200/JCO.21.01935
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。